Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
ATLANTA, Sept. 13, 2016 -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Wednesday, September 14, 2016 at 4:30 p.m. ET to review the Company’s financial results for the three month period and 2016 fiscal year ended June 30, 2016 and will provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results the same day, prior to the conference call.
In order to participate in the conference call, please dial (877) 312-5422 (domestic) or (253) 237-1122 (international) and refer to conference ID number 74878442. The live webcast can be accessed under the Investors section of the Company’s website at www.aviragentherapeutics.com.
About Aviragen Therapeutics, Inc.
Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: vapendavir, an oral treatment for human rhinovirus upper (HRV) respiratory infections in moderate-to-severe asthmatics currently being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor that has received Fast Track designation by the U.S. FDA, in Phase 2 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.aviragentherapeutics.com.
Contacts: Mark Colonnese Executive Vice President and Chief Financial Officer Aviragen Therapeutics, Inc. (678) 221-3381 [email protected] Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
